



**Registrant's telephone number, including area code: (908) 673-9000**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 1.01. Entry into a Material Definitive Agreement.**

On February 8, 2018, Celgene Corporation, a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the several underwriters named therein (collectively, the “Underwriters”), providing for its underwritten public offering of \$500,000,000 aggregate principal amount of 2.875% Senior Notes due 2021, \$1,000,000,000 aggregate principal amount of 3.250% Senior Notes due 2023, \$1,500,000,000 aggregate principal amount of 3.900% Senior Notes due 2028, and \$1,500,000,000 aggregate principal amount of 4.550% Senior Notes due 2048 (collectively, the “Notes”). The offer and sale of the Notes is registered under the Securities Act of 1933, as amended, pursuant to an automatic shelf registration statement on Form S-3 (File No. 333-214279) filed with the Securities and Exchange Commission on October 27, 2016. The Company intends to use the net proceeds from the offering to finance a portion of its acquisition of Juno Therapeutics, Inc. and to pay fees and expenses associated therewith and with this offering.

The Underwriting Agreement contains customary representations, warranties and agreements of the Company and customary conditions to closing, indemnification rights and obligations of the parties. The Company expects the transaction to close on or about February 20, 2018.

Some of the Underwriters and their affiliates have engaged in, and may in the future engage in, financial advisory, investment banking and other commercial dealings in the ordinary course of business with the Company, or its affiliates, including acting as lenders under various loan facilities. They have received, and may in the future receive, customary fees and commissions for these transactions.

The description of the Underwriting Agreement in this Form 8-K is a summary and is qualified in its entirety by the terms of the Underwriting Agreement. A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Form 8-K and is incorporated herein by reference.

**Item 8.01. Other Events.**

On February 9, 2018, the Company issued a press release announcing the pricing of its public offering of \$500,000,000 aggregate principal amount of 2.875% Senior Notes due 2021, \$1,000,000,000 aggregate principal amount of 3.250% Senior Notes due 2023, \$1,500,000,000 aggregate principal amount of 3.900% Senior Notes due 2028 and \$1,500,000,000 aggregate principal amount of 4.550% Senior Notes due 2048. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

1.1 Underwriting Agreement, dated as of February 8, 2018, among the Company and Citigroup Global Markets Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the several Underwriters named therein.

99.1 Press release of the Company dated February 9, 2018, announcing the pricing of its underwritten public offering of \$500,000,000 aggregate principal amount of 2.875% Senior Notes due 2021, \$1,000,000,000 aggregate principal amount of 3.250% Senior Notes due 2023, \$1,500,000,000 aggregate principal amount of 3.900% Senior Notes due 2028, and \$1,500,000,000 aggregate principal amount of 4.550% Senior Notes due 2048.

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE CORPORATION**

Date: February 9, 2018 By: /s/ Peter N. Kellogg  
Peter N. Kellogg  
Executive Vice President and  
Chief Financial Officer  
(principal financial and accounting officer)

Exhibit Index

Exhibit No. Description

- 1.1 Underwriting Agreement, dated as of February 8, 2018, among the Company and Citigroup Global Markets Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the several Underwriters named therein.
- 99.1 Press release of the Company dated February 9, 2018, announcing the pricing of its underwritten public offering of \$500,000,000 aggregate principal amount of 2.875% Senior Notes due 2021, \$1,000,000,000 aggregate principal amount of 3.250% Senior Notes due 2023, \$1,500,000,000 aggregate principal amount of 3.900% Senior Notes due 2028, and \$1,500,000,000 aggregate principal amount of 4.550% Senior Notes due 2048.